Cellebrite DI (NASDAQ:CLBT) Price Target Lowered to $15.00 at Lake Street Capital

Cellebrite DI (NASDAQ:CLBT) had its price target reduced by equities research analysts at Lake Street Capital from $21.00 to $15.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective points to a potential upside of 34.65% from the stock’s current price.

Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Needham & Company LLC dropped their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday. Finally, DA Davidson reduced their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Cellebrite DI has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Cellebrite DI Trading Up 3.1%

Shares of CLBT stock traded up $0.34 on Friday, reaching $11.14. The company’s stock had a trading volume of 7,828,758 shares, compared to its average volume of 2,139,398. The stock’s fifty day simple moving average is $14.52 and its 200-day simple moving average is $14.05. Cellebrite DI has a 1 year low of $9.58 and a 1 year high of $19.98. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.06. The company had revenue of $131.14 million for the quarter, compared to the consensus estimate of $131.87 million. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. Equities research analysts forecast that Cellebrite DI will post 0.41 earnings per share for the current year.

Insiders Place Their Bets

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares in the company, valued at $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 297,934 shares of company stock valued at $4,631,972 over the last three months. 5.70% of the stock is owned by company insiders.

Institutional Trading of Cellebrite DI

Several institutional investors have recently added to or reduced their stakes in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its position in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the period. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI in the third quarter worth approximately $40,000. CWM LLC raised its holdings in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the period. Elevation Wealth Partners LLC bought a new stake in shares of Cellebrite DI during the 2nd quarter worth approximately $44,000. Finally, First Horizon Corp lifted its stake in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after acquiring an additional 2,337 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analysts continue to see upside despite reducing their estimates. JPMorgan lowered its price target from $20 to $16 while retaining an Overweight rating; D.A. Davidson cut its target from $22 to $15 but maintained Buy; and Needham reduced its target from $15 to $12.50 while also keeping a Buy rating. The revised targets remain above the recent trading level. Analyst price-target updates
• Positive Sentiment: Second-quarter adjusted EPS of $0.11 exceeded the commonly cited analyst estimate of $0.05, and subscription revenue continued to grow. Management also raised its adjusted EBITDA target, providing some support for profitability. Cellebrite earnings release
• Positive Sentiment: Unusually heavy call-option activity, with nearly 20,000 contracts traded versus average volume of about 586, suggests some traders are positioning for a rebound. This is a speculative signal rather than a change in fundamentals.
• Neutral Sentiment: Cellebrite completed a planned CEO succession, appointing Shiven Ramji to replace Thomas E. Hogan. The transition could lead to a strategic reset, but it also adds uncertainty as investors reassess the company’s growth plans. CEO succession announcement
• Negative Sentiment: The primary catalyst for the decline was weaker forward guidance. Third-quarter revenue is forecast at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. Cellebrite also reduced its 2026 annual recurring revenue outlook, signaling slower growth.
• Negative Sentiment: Revenue of $131.14 million slightly missed expectations of $131.87 million, and ARR reportedly fell short of prior guidance. The revenue and recurring-revenue misses outweighed the quarterly EPS beat. Cellebrite Q2 earnings analysis
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations and whether previous projections and disclosures were accurate. These are allegations, not findings, but they increase legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Outgoing CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect the leadership transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.